ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold on the back of the FDA's rejection of its Lymphoseek application and lack any of visibility on the FDA's review process going forward. The firm also slashes its price target to $2.50 from $7.